Last reviewed · How we verify

Clindamycin + Gentamicin

Mercy Health Ohio · FDA-approved active Small molecule

Clindamycin and gentamicin are a combination antibiotic therapy that inhibits bacterial protein synthesis through different mechanisms to provide broad-spectrum coverage against aerobic and anaerobic pathogens.

Clindamycin and gentamicin are a combination antibiotic therapy that inhibits bacterial protein synthesis through different mechanisms to provide broad-spectrum coverage against aerobic and anaerobic pathogens. Used for Polymicrobial infections including intra-abdominal infections, Gynecological infections, Respiratory tract infections with mixed aerobic and anaerobic pathogens.

At a glance

Generic nameClindamycin + Gentamicin
Also known asCleocin + Garamycin
SponsorMercy Health Ohio
Drug classAntibiotic combination (lincosamide + aminoglycoside)
TargetBacterial ribosome (50S subunit for clindamycin; 30S subunit for gentamicin)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Clindamycin is a lincosamide that binds to the bacterial 50S ribosomal subunit to inhibit protein synthesis, with particular activity against anaerobes and gram-positive organisms. Gentamicin is an aminoglycoside that binds to the 30S ribosomal subunit and inhibits protein synthesis, providing coverage against aerobic gram-negative bacteria and some gram-positive organisms. Together, they provide synergistic coverage for polymicrobial infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: